Scientific communications

Explicyte and Institut Bergonié associate in a clinical trial report publication

02 / 25 / 2021

Explicyte and Institut Bergonié associate in a clinical trial report publication

Digital pathology for tumor immune infiltrate analysis and patient selection
To assess whether or not the tumor immune contexture was predictive of response to the Avelumab-Regorafenib combination regimen, Explicyte developed and ran, on baseline FFPE samples, a multiplexed immunohistofluorescence panel consisting of CD8, PD1, PDL1, CD163, IDO1, and PanKeratin markers, in addition to Dapi (Discovery XT, Roche Diagnostics).

Explicyte is proud to be a certified Nanostring partner - Let’s start the Digital Spatial Profiling revolution together!

12 / 10 / 2020

Explicyte is proud to be a certified Nanostring partner - Let’s start the Digital Spatial Profiling revolution together!

It therefore becomes primordial to benefit from a technological platform that allows to deal with the tumor biology complexity/heterogeneity and get specific investigations in compartments of interest (e.g. tumor vs stroma). Thanks to the GeoMx platform (Nanostring Inc.), which combines the spatial resolution of immunohistofluorescence with the high-plex gene/protein expression analysis, the Digital Spatial Profiling (DSP) revolution has started.

A syngeneic renal cancer mouse model for the discovery of novel immuno-oncology therapies

11 / 18 / 2020

A syngeneic renal cancer mouse model for the discovery of novel immuno-oncology therapies

We have fully set up and characterized a syngeneic Renca renal mouse model recapitulating most of the human RCC condition features. Indeed, our model displays an enriched tumor microvascular environment and relatively low immune infiltration - nevertheless constituted of a strong Myeloid-Derived Suppressor Cells (MDSCs) proportion.

 

A syngeneic orthotopic EMT6 breast mouse model for preclinical immuno-oncology testing of novel anti-cancer strategies

07 / 09 / 2020

A syngeneic orthotopic EMT6 breast mouse model for preclinical immuno-oncology testing of novel anti-cancer strategies

Because of metastatic development of the disease, among other characteristics, and regardless of survival data, breast cancer was shown to be particularly difficult to treat. However, metastases as well as resistance to therapies continue to be a great challenge and the development of new therapeutic strategies is increasingly necessary.